Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review
Y Yamamoto, K Kodama, T Maniwa… - Journal of Cardiothoracic …, 2017 - Springer
Background The usefulness of residual tumor resection after epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) treatment remains unclear. We describe two …
receptor tyrosine kinase inhibitor (EGFR-TKI) treatment remains unclear. We describe two …
[HTML][HTML] A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III non–small-cell lung cancer harboring EGFR mutations …
H Akamatsu, H Harada, S Tokunaga, N Yoshimura… - Clinical lung cancer, 2019 - Elsevier
Locally advanced non–small-cell lung cancer (NSCLC) is curable. Standard treatment is
concurrent chemoradiotherapy, but its efficacy with cytotoxic agents seems to reach a …
concurrent chemoradiotherapy, but its efficacy with cytotoxic agents seems to reach a …
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation …
H Tada, T Mitsudomi, T Misumi, K Sugio… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …
[PDF][PDF] Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report
T Kijima, M Suzuki, K Ueda, S Minami… - … and Clinical Cancer …, 2007 - researchgate.net
The tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) gefitinib
has beneficial effect in some patients with refractory advanced non-small cell lung cancer …
has beneficial effect in some patients with refractory advanced non-small cell lung cancer …
[HTML][HTML] The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
XT Zhang, LY Li, XL Mu, QC Cui, XY Chang, W Song… - Annals of oncology, 2005 - Elsevier
Background: The aim of the study was to evaluate the efficacy of gefitinib and the epidermal
growth factor receptor (EGFR) mutation to gefitinib response in a series of Chinese patients …
growth factor receptor (EGFR) mutation to gefitinib response in a series of Chinese patients …
Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for lung adenocarcinoma
S Miyamoto, Y Ohkuma, Y Takagi… - Gan to Kagaku ryoho …, 2010 - europepmc.org
Background EGFR-TKI yields a long survival period in cases of non-small cell lung cancer
(NSCLC), especially those with EGFR gene mutations, but the effect is limited. The later …
(NSCLC), especially those with EGFR gene mutations, but the effect is limited. The later …
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or …
J Hyung, H Yoon, CM Choi, S Yoon, DH Lee… - Journal of Cancer …, 2023 - Springer
Purpose Whether prior radiotherapy (RT) affects the response of EGFR-mutated non-small
cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitor (TKI) remains elusive. Methods …
cell lung cancer (NSCLC) to EGFR tyrosine kinase inhibitor (TKI) remains elusive. Methods …
Effect of gefitinib combined with chemotherapy in patients with advanced NSCLC: A retrospective cohort study
L Dai, W Wang, W Li, Y Wu, K Qu - International Journal of General …, 2022 - Taylor & Francis
Background There are currently no methods for the treatment of reversible drug-resistant
EGFR-TKI lung cancer in the clinical setting, and thus, the patients finally return to the …
EGFR-TKI lung cancer in the clinical setting, and thus, the patients finally return to the …
[HTML][HTML] First-line gefitinib in patients aged 75 or older with advanced non–small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study
M Maemondo, Y Minegishi, A Inoue… - Journal of Thoracic …, 2012 - Elsevier
Introduction: Recent studies have demonstrated that first-line treatment with gefitinib, an
epidermal growth factor receptor (EFGR)–targeted tyrosine kinase inhibitor, is significantly …
epidermal growth factor receptor (EFGR)–targeted tyrosine kinase inhibitor, is significantly …
[HTML][HTML] Effectiveness of gefitinib against non–small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q
S Watanabe, Y Minegishi, H Yoshizawa… - Journal of thoracic …, 2014 - Elsevier
Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …